title: Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
abstract: Monoclonal antibody (MAb) ICR41.1i (rat IgG2a) is specific for a conformation-dependent epitope of human immunodeficiency virus type 1 (HIV-1) V3 , and MAb F58 (mouse IgG1) recognizes the peptide IXXGPGR, at the tip of the V3 loop. Both MAbs neutralized HIV-1 strain IIIB in C8166 and HeLa-T4(CD4) cells. Neutralization by either MAb did not inhibit attachment of virus to target cells as determined by FACS analysis, ELISA or immunofluorescence, and such attachment was absolutely dependent on the availability of CD4 molecules. F58 inhibited virus-induced cell-cell fusion, and reduced internalization of virions in direct proportion to neutralization. In contrast, ICR41.li had no effect on HIV-1-mediated cell fusion or on internalization of virus. It was concluded that MAb F58 neutralized infectivity by inhibiting fusion of the virus with the cell and internalization of the viral core, and that ICR41.1i neutralized by inhibiting a post-fusion-internalization event. The possible mechanism by which a neutralizing antibody binds to the V3 loop and affects the function(s) of structures inside the virion is discussed. Lastly, postattachment neutralization (PAN) was investigated. F58 mediated PAN at 21 degrees C and 35 degrees C. However, ICR41.1i gave PAN at 21 degrees C but not at 35 degrees C, suggesting that a temperature-dependent event affecting the V3 loop had abrogated neutralization. Overall, it appears that antibodies to different epitopes within the V3 loop neutralize by affecting very different functions of the virus.
authors.affiliation: Department of Biological Sciences, University of Warwick, UK.
authors.forename: S J
authors.initials: SJ
authors.lastname: Armstrong
authors.forename: T L
authors.initials: TL
authors.lastname: McInerney
authors.forename: L
authors.initials: L
authors.lastname: McLain
authors.forename: B
authors.initials: B
authors.lastname: Wahren
authors.forename: J
authors.initials: J
authors.lastname: Hinkula
authors.forename: M
authors.initials: M
authors.lastname: Levi
authors.forename: N J
authors.initials: NJ
authors.lastname: Dimmock
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001667:Binding, Competitive; D015704:CD4 Antigens / Q000276:immunology; D002459:Cell Fusion; D004229:Dithiothreitol / Q000494:pharmacology; D019084:Fluorescent Antibody Technique, Indirect; D015483:HIV Antibodies / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology*; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology*; D051381:Rats; D011991:Receptors, Virus / Q000276:immunology; D013696:Temperature; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D011991:Receptors, Virus; D004229:Dithiothreitol